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Solid gastrointestinal tumours have been reported to express
sex steroid receptors (e.g. oestrogen (McCleadon et al., 1977;
Leake et al., 1980; Niski et al., 1987), progesterone (Sica
et al., 1984)) or specific receptors for gastrointestinal hor-
mones (e.g. gastrin (Rae-Venter et al., 1981)), somatostatin
(Viguerie et al., 1980) and vasoactive intestinal peptide
(Estival et al., 1983). The monoclonal antibody D5 detects
the 29 kD phosphoprotein, p29. D5 was first raised against
partially purified human uterine oestrogen receptor (Coffer et
al., 1977). In primary breast tumours D5 staining correlated
significantly with oestrogen receptor status but not pro-
gesterone receptor status (Cano et al., 1986). D5 staining of
the primary tumour, like oestrogen receptor status, correlated
well with response to endocrine therapy (Cano et al., 1986).
This correlation in patients with breast cancer between D5
immunostaining and response to endocrine therapy has been
confirmed (Heyderman et al., 1989). However, it has been
shown that while oestrogen receptor is localised mainly to the
nucleus in breast cancer, D5 staining is mainly cytoplasmic
(King et al., 1985).
Our own group has previously reported on the influence of
D5 immunoreactivity and the effect of the anti-oestrogen
tamoxifen on survival in patients with gastric carcinoma
(Harrison et al., 1989). Patients with D5 positive tumours
had a significantly decreased survival time. Tamoxifen
therapy in patients with D5 positive tumours resulted in a
further significant decrease in survival. Tamoxifen therapy
did not effect survival in patients with D5 negative tumours.
In this study we have therefore investigated the expression
of D5 in primary colorectal cancers by immunohistology and
assessed the prognostic significance of such expression.
Sixty-eight patients (36 women, 32 men) with colorectal
carcinoma were entered into this study. Twenty-one cancers
originated in the right colon, 24 in the left colon and 23 in
the sigmoid colon or rectum. At presentation all tumours
were staged according to Dukes' classification to which was
added stage D (i.e. metastases): eight had stage A tumours,
32 stage B, 14 stage C and 14 stage D. Tumours were also
graded histologically; 6 were well differentiated, 48 moder-
ately differentiated and 14 poorly differentiated.
None of the 68 patients were treated post-operatively with
systemic therapy. All patients were followed up regularly in
the out-patient clinic.
Of the 54 patients who initially presented with loco-
regional disease and had excision of the primary tumour,
time to recurrence was known for 52 of these patients and
these 52 patients have been used in calculating the prob-
ability of recurrence after potentially curative surgery. Sur-
vival data is available on 67 of the 68 patients.
The significance of differences between groups in either
recurrence or survival were tested using the Mantel-Cox/
generalised Savage test.
D5 immunoreactivity was measured on all 68 primary
colorectal tumours as previously described (Harrison et al.,
1989). All tumour resections were assessed by one pathologist
(IOE) and described as D5 negative (no tumour cells stain-
ing) or positive. Tumours showing positivity were further
divided into three subgroups - i.e. slight focal positivity
(<5% cells positive), moderate focal positivity (5-80%
positive) and tumours showing diffuse positivity (>80%
positive).
DNA ploidy of the primary tumour was measured by flow
cytometry as previously reported from this unit (Armitage et
al., 1985).
The relationship between D5 immunoreactivity and the
other prognostic variables was tested by the chi-squared test
with Yates correction. Disease free survival and overall sur-
vival curves were calculated by the life table method using
the BMDP package (Dixon, 1985). Two analogues of non-
parametric rank tests, the Mantel-Cox (Mantel, 1966) and
the Breslow test (Breslow, 1970) were used to determine
whether the survival curves obtained for the defined groups
were significantly different.
Twenty-nine patients had D5 negative tumours. Of the 39
patients who had D5 positive tumours 12 had slight focal
positivity, 26 had moderate focal positivity while the remain-
ing patient had diffuse immunopositivity. There was no cor-
relation between D5 status and the patients sex (Table I).
There was also no correlation between D5 status and tumour
site, tumour stage, histological grade of malignancy or
tumour ploidy (Table I).
D5 status (negative vs positive) was correlated with the
probability of recurrence (Mantel-Cox statistic 0.238, 1 d.f.;
P = 0.63) (Figure 1). Patients with D5 positive tumours were
further subdivided into slightly focal, moderately focal and
diffusely positive staining: there was no correlation between
the degree of immunoreactivity and recurrence (Mantel-Cox
statistic = 1.11, 3 d.f.; P = 0.78). Although there was no
difference in D5 status by patients' sex the probability of
Table I Relationship between D5 status of primary tumour and
patients and tumour characteristics
D5 Status
Positive Negative P value
Sex
Male 18 14 N.S.
Female 21 15
Tumour site
Right colon 10 11
Left colon 13 1 1 N.S.
Recto-sigmoid 16 7
Tumour stage
Dukes' A 3 5
Dukes' B 19 13
Dukes' C 11 3 N.S.
Dukes' D 6 8
Histological grade
Well differentiated 2 4
Moderately differentiated 29 19 N.S.
Poorly differentiated 8 6
Ploidy status
Diploid 16 8
Aneuploid 23 21 N.S.
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Figure 1 Probability of recurrence by D5 status. -*- D5 Pos;
-+- D5 neg.
recurrence by D5 status was analysed separately for male
(Mantel-Cox statistic = 0.2, 1 d.f.; P = 0.6) and female
patients (Mantel-Cox statistic = 0.1, 1 d.f.; P = 0.7); there
was no correlation.
D5 status showed no correlation with overall survival
(Figure 2). There was also no correlation between the degree
of D5 immunoreactivity and survival (Mantel-Cox statistic
= 0.96, 3 d.f.; P =0.81). At 30 months this study had a 80%
power of showing a 25% difference in survival between the
two groups at the 5% level.
The D5 antibody used in this study identifies an oestrogen
receptor related protein rather than the oestrogen receptor
itself. We chose this antibody because we had shown that D5
immunoreactivity was an independently significant prognostic
factor in another solid gastrointestinal tumour.
In gastric cancer we have previously shown that 56% of
primary tumours show positive D5 immunoreactivity (Harri-
son et al., 1989). In this study of colorectal cancer 57% of
primary tumours showed positive staining for D5. As in
gastric cancer there was no correlation between D5 immuno-
reactivity and patient sex, tumour stage or histological grade
of malignancy. In addition this study found no correlation
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between D5 immunoreactivity and tumour DNA ploidy.
However D5 status of colorectal tumours did not correlate
with recurrence free survival or overall survival. One ex-
planation may be that the study had only an 80% change of
showing a large (i.e. 25%) difference in survival. In gastric
cancer most patients present with advanced disease. Deaths
are frequent in such patients and the large number of events
give power to the survival analysis. Since most patients with
gastric cancer have advanced disease at presentation the in-
trinsic biology of the tumour is important in patients' sur-
vival. This may therefore explain why the intrinsic tumour
biological factor D5 is expressed in a similar percentage of
gastric and colorectal primary tumours, but has been shown
to be of prognostic significance only in gastric cancer. Of the
68 patients with colorectal cancer in this study more than
50% are still alive after a median follow-up of 40 months.
The relationship between D5 immunoreactivity and oestro-
gen receptor (ER) expression has not been established in
colorectal cancer. While the lack ofprognostic value of D5 in
colorectal cancer is disappointing, its significance with respect
to the sensitivity of colorectal cancer to sex steroid hormones
is uncertain.
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